SCHEMBL219323

SCHEMBL219323

CC(c1oc2ccccc2c(=O)c1-c1ccccc1)n1nc(C(C)(C)O)c2c(N)ncnc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.55
PIK3CG P48736 9/20 0.49
PIK3R1 P27986 1/20 0.49
CSNK1E P49674 1/20 0.49
PIK3CB P42338 5/20 0.42
PIK3R2 O00459 2/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
PIK3CA P42336 4/20 0.39
SRC P12931 5/20 0.38
ABL1 P00519 4/20 0.38
EGFR P00533 3/20 0.38
HCK P08631 3/20 0.38
KDR P35968 3/20 0.38
MTOR P42345 3/20 0.38
EPHB4 P54760 3/20 0.38
PRKDC P78527 3/20 0.38
PI4KB Q9UBF8 2/20 0.38
RET P07949 1/20 0.37
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11145 0.88 PIK3CD (0.52) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL29651758 0.88 PIK3CD (0.52) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL7755 0.86 PIK3CD (0.57) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL29651701 0.86 PIK3CD (0.57) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL129935 0.83 PIK3CD (0.67) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL29651723 0.83 PIK3CD (0.67) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL19113532 0.82 PIK3CD (0.52) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL11693 0.80 PIK3CD (0.61) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL29651820 0.80 PIK3CD (0.61) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB
SCHEMBL12608404 0.80 PIK3CD (0.61) PIK3CDPIK3CGPIK3R1CSNK1EPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.